Chimeric PSGL-1 Protein Stable Homodimer Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant PSGL-1 proteins face challenges in achieving high expression levels and correct post-translational modifications, particularly in forming stable homodimers for effective selectin binding, which is crucial for diagnostic and therapeutic applications.
Innovation Solution
A recombinant PSGL-1 chimeric protein is developed using a leucine zipper domain for non-covalent dimerization, allowing for efficient expression and secretion in mammalian cells, and is correctly post-translationally modified with disulfide bonds, enabling effective binding to selectin proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant PSGL-1 proteins are produced using conventional methods, then expression levels can be achieved, but the formation of stable homodimers and correct post-translational modifications is insufficient
Solution Approach 1:
The patent introduces a leucine zipper domain as an intermediary dimerization module that mediates the formation of stable homodimers. This domain acts as a bridge between PSGL-1 monomers, facilitating reliable dimer formation without compromising expression levels. The leucine zipper serves as a dedicated dimerization interface that overcomes the insufficient homodimer formation observed in conventional production methods.
2Manufacturing precision
If recombinant PSGL-1 proteins are produced using conventional methods, then some expression is achieved, but correct post-translational modifications are not obtained
Solution Approach 1:
The patent employs parameter changes by modifying the protein structure to include a specific leucine zipper domain with defined amino acid sequence and structural characteristics. This structural parameter change enables correct post-translational modifications while maintaining high expression levels, as the leucine zipper domain provides a suitable substrate for proper folding and modification enzymes.
3Reliability
If a leucine zipper domain is used for dimerization, then stable homodimers are formed, but the complexity of the protein structure increases
Solution Approach 1:
The patent applies segmentation by dividing the PSGL-1 protein into distinct functional modules: the PSGL-1 domain for selectin binding and the leucine zipper domain for dimerization. This modular segmentation allows each domain to perform its specific function independently, ensuring stable dimer formation while keeping the overall structure organized and functional rather than merely complex.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in high-level expression and correct post-translational processing of the PSGL-1 protein, forming stable homodimers that effectively target selectins, facilitating improved diagnostic and therapeutic applications.
Implementation Method 1
a leucine zipper domain able to form a right-handed α helix thus promoting dimerization through protein-protein interaction
Implementation Method 2
a disulfide bonds promoting region comprising at least one cysteine available to form a disulfide bond with another cysteine in a monomeric chimeric protein counterpart, so that the two chimeric protein monomers are covalently linked to each other by at least a disulfide bond
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes.